// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























41730 Abstracts

TLR3-induced immune response using PLGA nanoparticles for dendritic cell-based cancer immunotherapy

HEEDONG HAN - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin

Yi-Jun Wang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Doxorubicin

Targeted, controlled anticancer drug delivery and release with magnetoelectric nanoparticles

Alexandra Rodzinski - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Exosomal encapsulation of doxorubicin reduces the cardiac toxicity of mice

Flavio Rizzolio - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Doxorubicin

Development and characterization of an injectable copper clioquinol formulation: repurposing of a topical antifungal for treatment of cancer

Moe Wehbe - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

clioquinol

Using AFM to predict the specificity of tumor targeting nanomedicine in vivo

Peng Guo - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Novel nanoparticle formulation of Plumbagin for pancreatic cancer treatment

Bilal B. Hafeez - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

CXCL12

Multiple antigens stimulating cellular therapy increases immune responses in patients with hepatocellular carcinoma

Yanyan Han - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Induction of 51 integrin expression rescues geriatric CAR-T cell function

Prajna Guha - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pembrolizumab and ipilimumab reduce human RKO colon carcinoma tumor growth in HLA matched CD34-NSG humanized mice

Marcio Lasaro - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Study of PDL-1 regulation and expression in glioblastoma and its role in cancer resistance

Michele Russo - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Temozolomide

Dual inhibition of cancer stemness and immune checkpoint genes by targeting Stat3

Yuan Gao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Membranous expression of programmed cell death-ligand 1 (PDL1) on cancer cells is induced by cisplatin in an ATR dependent manner

Lea Schaaf - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Discovery, development and characterization of a new class of therapeutic anti-PD-1 antibody

Lei Wang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Positive correlation between the gamma-H2AX and PD-L1 expressions in lung squamous cell carcinoma

Atsushi Osoegawa - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cbl-b inhibitors as novel intra-cellular checkpoint inhibitors for cancer immunotherapy

Saket Agarwal - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anti-CTLA4

Evaluation of PD-L1 expression in ovarian carcinosarcoma by immunohistochemistry and RNAscope in-situ hybridization

Li Liang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

IO125 is a potent inducer of tumor immunogenicity

Sanghamitra Mylavarapu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Long lasting CR status of stage IV gall bladder cancer and colon cancer after combined treatment including autologous formalin-fixed tumor vaccine (AFTV)

Fumito Kuranishi - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Understanding immune phenotypes and their spatial relationships to breast adenocarcinoma in FFPE tissues

Yi Zheng - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Copyright © 2026. QuantiNova All rights reserved